Summary
The in vivo effects on the fibrinolytic and coagulation system of infusing acylated
streptokinase-plasminogen complex (BRL 26921; 5, 7 and 12 mg) or streptokinase (250,000
u) were determined in healthy male volunteers. While this dose of streptokinase resulted
in depletion of plasminogen and antiplasmin, and in some cases of fibrinogen and coagulation
factors V and VIII, the equivalent 7 mg dose of BRL 26921 had little effect on these
parameters. 12 mg BRL 26921 had some systemic effects on the fibrinolytic system.
For initial clinical studies a dose of 10 mg BRL 26921 would seem appropriate.
Both drugs induced an anamnestic rise in streptokinase antibody, whereas no change
in liver function tests were observed. A delayed mild febrile reaction was observed
in some subjects following infusion of streptokinase or BRL 26921. Clinical, laboratory,
and subjective monitoring revealed no other adverse effects with either drug.
Key words
Fibrinolysis - Streptokinase - Plasminogen
